

New Ablative Fractional Laser System Makes Debut

BY DOUG BRUNK
San Diego Bureau

A laser system for skin rejuvenation that delivers ablative fractional resurfacing technology made its official debut at the annual meeting of the American Academy of Dermatology.

Manufactured by Mountain View, Calif.-based Reliant Technologies, the 10,600-nm CO₂ Fraxel re:pair laser uses a continuous motion handpiece to create microscopic "zones of treatment" evenly across the surface of the skin. Clinical studies have demonstrated that it can treat up to 6 g of dermal tissue in a single treatment session with depths that range from 300 micrometers to 1.6 mm, according to the manufacturer.

In May of 2007 the device was cleared by the Food and Drug Administration for ablation, coagulation, and skin resurfacing. In December of 2007 it received FDA 510(k) clearance for the treatment of wrinkles, rhytids, furrows, fine lines, textural irregularities, pigmented lesions, and vascular dyschromia. The current retail price of the Fraxel re:pair system is \$129,000.

Studies of the device have included about 500 treatments over the last 2.5 years. In one recent study of its use on the forearm skin of 24 subjects with Fitzpatrick skin types II-IV, researchers tested pulse energies that ranged from 5 to 40 mJ and used hematoxylin and eosin to assess the lesions histologically (*Lasers Surg. Med.* 2007;39:96-107). They found that changing the pulse energy from 5 to 30 mJ created a threefold increase in lesion depth and a twofold increase in width.

"Interestingly, ablative fractional resurfacing demonstrated much more rapid reepithelialization when compared to its nonfractional predecessors, whether powered



A patient is shown before (left) and 1 month after treatment with the Fraxel re:pair laser, which is said to demonstrate "more rapid reepithelialization."

In most cases, one treatment is sufficient and downtime is 2-4 days depending on the parameters used. "On day 5 you have redness and swelling," said Dr. Zachary, an unpaid consultant to Reliant Technologies.

Dr. Zachary said that he has limited experience using the device in dark-skinned patients, but "I absolutely intend to use it [on dark-skinned patients] on a regular basis," he said. "Darker skin types are going to have problems with skin pigmentation. To prevent it, we are pretreating for at least 2 weeks with a bleaching agent such as hydroquinone 4% cream, which will reside within the normal untreated skin after you have treated a fraction of the skin. That area that you do not treat will have a reservoir of hydroquinone which tends to prevent increased postinflammatory hyperpigmentation."

Trials are currently underway to study the use of the Fraxel re:pair system for treating acne scars, surgical scars, and stri-

ae. Dr. Zachary said that patients with severe acne scarring "are probably going to have two to three treatments separated by about a month each."

Dr. Robert A. Weiss, president-elect of the American Society for Dermatologic Surgery, called the Fraxel re:pair system an "elegant device" and noted that ablative fractional technology "is the next phase of fractional. It really does give a lot more improvement."

Dr. Weiss, who practices in Hunt Valley, Md., said that he currently uses a competing fractional laser procedure from Lumenis Ltd. called ActiveFX, which is delivered by the company's UltraCool Encore CO₂ system. Dr. Weiss is a member of the medical advisory board for Lumenis Ltd.

Dr. Zachary disclosed that he has received equipment and honoraria from Reliant Technologies and that he serves as a consultant for other laser companies. ■

Porcine Collagen Could Be Answer to Filler Longevity

BY TIMOTHY F. KIRN
Sacramento Bureau

LAS VEGAS — Porcine collagen crosslinked with D-ribose probably lasts as long or longer than does hyaluronic acid when used as a cosmetic filler for lips and nasolabial folds, Dr. Gary Monheit said at the annual meeting of the American Society of Cosmetic Dermatology and Aesthetic Surgery.

The product, Evolence (Dermicol-P35) manufactured by ColBar LifeScience Ltd. (Israel), is approved for use in Europe and Canada and is expected to be approved in the United States, according to Dr. Monheit, principal investigator in the U.S. trial. The company has submitted an approval application to the Food and Drug Administration.

The trial's split-face design compared Evolence injection with hyaluronic acid (Restylane) injection in the nasolabial folds of 149 patients. After 6 months, there was no significant difference in the mean amount of correction the patients had on either side, as judged by study observers using the Modified Fitzpatrick Wrinkle Scale score (*Dermatol. Surg.* 2007;33:S213-21). Dr. Monheit disclosed receiving sup-

plies and financial support from ColBar.

The secret to Evolence's longevity is thought to be the high level of crosslinking between the individual collagen fibers in the material, he said. "Because of this extra crosslinking, this is a very stable product that lasts over a year, possibly 2 years."

At 1-year follow-up, 90% of the patients that received Evolence still had some degree of improvement, said Dr. Monheit of the University of Alabama, Tuscaloosa. Evolence has been found to last up to 2 years when implanted into rabbit ears.

Raw material for Evolence comes from the tendons of pigs. In the first step of processing, the pig collagen's natural crosslinking is broken down by pepsin into monomeric collagen. Then the telopeptide of each collagen strand is removed because that part is the most immunogenic.

Pig collagen is used by ColBar because it is probably less immunogenic than beef collagen, he said.

Once the telopeptides are removed the material is again crosslinked, but instead of using glutaraldehyde or some other potentially problematic chemical to create the crosslinking, ColBar uses D-ribose, Dr. Monheit said. ■

Deep Heating Skin Found to Improve Fractional Resurfacing

BY BRUCE K. DIXON
Chicago Bureau

CHICAGO — The clinical results of fractional skin resurfacing may be improved by pretreatment with an infrared laser or broadband infrared light source, according to a pilot study presented at the annual meeting of the American Society for Dermatologic Surgery.

"In the treatment of scars and wrinkles, combination deep heating immediately prior to fractional resurfacing gives better results in less time than fractional laser treatment alone," said Dr. Robert Weiss, of the dermatology department at Johns Hopkins University, Baltimore.

For this study, a control group of 20 patients received the usual fractional resurfacing on the face or neck with the Lux 1540 (Palomar Medical Technologies), while 20 others first received deep heating with an infrared pulsed laser using the 1,320-nm CoolTouch 3 (CoolTouch Inc.).

"Using the CoolTouch, we preheated the skin from a typical baseline temperature of 32° up to 40°, and then we applied the fractional resurfacing to the scar or

wrinkle with the 1540-nm stamped mode at 50 mJ per little dot," Dr. Weiss said.

The control group received four monthly treatments, while the deep heating plus fractional group received two monthly treatments, he said, adding that the results were evaluated out to 3 months after the last treatment.

Down times caused by erythema ranged from 12 to 24 hours in the control group and increased to 48-96 hours for those receiving the combination treatment. That compares with 48-96 hours for patients who receive CO₂ laser fraction treatment, Dr. Weiss explained.

Pretreatment with heat produced both faster and visually better results, Dr. Weiss said, adding that, in some cases, two combination treatments improved scarring as much as five fractional-only treatments.

The investigators concluded that the combination treatment demonstrated a 30% improvement in scars and rhytids, compared with fractional only, and reduced the number of treatments from four to two.

Dr. Weiss is a consultant for Palomar and CoolTouch and performs research for Palomar, Cynosure, and CoolTouch. ■